Scholarlink

Introduction <p>Antimicrobial resistance (AMR) is a critical global health threat, particularly in resource-constrained settings like Somalia, where fragile healthcare systems amplify the challenge. This study aimed to evaluate AMR patterns in clinical bacterial isolates over a five-year period at Jazeera University Laboratory Department in Mogadishu, Somalia, to identify prevalent resistant pathogens and assess resistance trends for commonly prescribed antibiotics.</p> Methods <p>A retrospective analysis examined 785 bacterial samples from clinical specimens (e.g., urine, blood, wound swabs) collected between January 2019 and December 2024. Isolates which included <i>Escherichia coli</i>,<i> Klebsiella pneumoniae</i>,<i> Staphylococcus aureus</i>,<i> Pseudomonas aeruginosa</i>,<i> Acinetobacter baumannii</i>,<i> or Enterobacter spp</i>., underwent susceptibility testing for Ampicillin (AMP), Amoxicillin/Clavulanate (AMC), Ceftriaxone (CRO), Ciprofloxacin (CIP), Gentamicin (GENTA), Nitrofurantoin (NIT), and Methicillin (METH) using disk diffusion method per CLSI guidelines. Data on age, sex, specimen source, isolation year, and resistance profiles were analyzed using SPSS, with chi-square tests to assess associations and temporal trends (<i>p</i> &lt; 0.05 indicating significance).</p> Results <p><i>Escherichia coli</i> (38.7%), <i>Staphylococcus aureus</i> (34.9%), and <i>Klebsiella pneumoniae</i> (22.9%) were the prevalent pathogens, primarily from urine cultures (47.1%). High resistance was observed for <i>Ampicillin</i> (AMP) in <i>Escherichia coli</i> (96.7%, <i>p</i> = 0.001), <i>Klebsiella pneumoniae</i> (93.9%, <i>p</i> = 0.074), and <i>Staphylococcus aureus</i> (90.1%, <i>p</i> = 0.008), and for <i>Amoxicillin/Clavulanate</i> (AMC) in <i>Escherichia coli</i> (78.9%, <i>p</i> = 0.001), <i>Klebsiella pneumoniae</i> (57.8%, <i>p</i> = 0.002), and <i>Staphylococcus aureus</i> (57.3%, <i>p</i> = 0.001). <i>Ceftriaxone</i> (CRO) resistance was high in <i>Escherichia coli</i> (61.8%, <i>p</i> = 0.001) and low in <i>Staphylococcus aureus</i> (16.8%, <i>p</i> = 0.001). <i>Ciprofloxacin</i> (CIP) resistance was moderately high in <i>Escherichia coli</i> (46.7%, <i>p</i> = 0.001) and lower in <i>Staphylococcus aureus</i> (22.3%, <i>p</i> = 0.001). <i>Gentamicin</i> (GENTA) and <i>Nitrofurantoin</i> (NIT) showed an overall lower resistance, particularly in <i>Escherichia coli</i> (16.8%, <i>p</i> = 0.001; 8.2%, <i>p</i> = 0.001) and <i>Staphylococcus aureus</i> (17.9%, <i>p</i> = 0.001; 7.3%, <i>p</i> = 0.001). <i>Staphylococcus aureus</i> exhibited significant <i>methicillin</i> resistance (40.5%, <i>p</i> = 0.001).</p> Conclusion <p>Widespread AMR, particularly to AMP, AMC, CRO, and CIP, the need for targeted antimicrobial stewardship, enhanced surveillance, and robust infection prevention strategies in Somalia’s resource-limited healthcare system to address the growing AMR crisis.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A five-year retrospective analysis of antimicrobial resistance patterns in clinical bacterial isolates from the Jazeera University Laboratory in Mogadishu, Somalia

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月26日

查看全文
  • Abdirahman Moallim Ibrahim,
  • Lul Mohamud Mohamed,
  • Abdullah Dahir H. Aweis,
  • Safiyo Qasim Fidow,
  • Farhia Abdullahi Mohamed,
  • Safiyo Mohamed Osman,
  • Fadumo Abdi Mohamed,
  • Ismail Ali Mohamud,
  • Naciima Mohamud Roble,
  • Marian Muse Osman,
  • Abdullahi Mohamed Mohamud,
  • Saadaq Adan Hussein,
  • Abdiwahab Sheikh Elmi Adam,
  • Abdullahi Adan Shaba

摘要

Introduction

Antimicrobial resistance (AMR) is a critical global health threat, particularly in resource-constrained settings like Somalia, where fragile healthcare systems amplify the challenge. This study aimed to evaluate AMR patterns in clinical bacterial isolates over a five-year period at Jazeera University Laboratory Department in Mogadishu, Somalia, to identify prevalent resistant pathogens and assess resistance trends for commonly prescribed antibiotics.

Methods

A retrospective analysis examined 785 bacterial samples from clinical specimens (e.g., urine, blood, wound swabs) collected between January 2019 and December 2024. Isolates which included Escherichia coli, Klebsiella pneumoniae, Staphylococcus aureus, Pseudomonas aeruginosa, Acinetobacter baumannii, or Enterobacter spp., underwent susceptibility testing for Ampicillin (AMP), Amoxicillin/Clavulanate (AMC), Ceftriaxone (CRO), Ciprofloxacin (CIP), Gentamicin (GENTA), Nitrofurantoin (NIT), and Methicillin (METH) using disk diffusion method per CLSI guidelines. Data on age, sex, specimen source, isolation year, and resistance profiles were analyzed using SPSS, with chi-square tests to assess associations and temporal trends (p < 0.05 indicating significance).

Results

Escherichia coli (38.7%), Staphylococcus aureus (34.9%), and Klebsiella pneumoniae (22.9%) were the prevalent pathogens, primarily from urine cultures (47.1%). High resistance was observed for Ampicillin (AMP) in Escherichia coli (96.7%, p = 0.001), Klebsiella pneumoniae (93.9%, p = 0.074), and Staphylococcus aureus (90.1%, p = 0.008), and for Amoxicillin/Clavulanate (AMC) in Escherichia coli (78.9%, p = 0.001), Klebsiella pneumoniae (57.8%, p = 0.002), and Staphylococcus aureus (57.3%, p = 0.001). Ceftriaxone (CRO) resistance was high in Escherichia coli (61.8%, p = 0.001) and low in Staphylococcus aureus (16.8%, p = 0.001). Ciprofloxacin (CIP) resistance was moderately high in Escherichia coli (46.7%, p = 0.001) and lower in Staphylococcus aureus (22.3%, p = 0.001). Gentamicin (GENTA) and Nitrofurantoin (NIT) showed an overall lower resistance, particularly in Escherichia coli (16.8%, p = 0.001; 8.2%, p = 0.001) and Staphylococcus aureus (17.9%, p = 0.001; 7.3%, p = 0.001). Staphylococcus aureus exhibited significant methicillin resistance (40.5%, p = 0.001).

Conclusion

Widespread AMR, particularly to AMP, AMC, CRO, and CIP, the need for targeted antimicrobial stewardship, enhanced surveillance, and robust infection prevention strategies in Somalia’s resource-limited healthcare system to address the growing AMR crisis.